Journal
CANCERS
Volume 13, Issue 16, Pages -Publisher
MDPI
DOI: 10.3390/cancers13164233
Keywords
breast cancer; tumor microenvironment; stromal response; fibrotic focus; tumor infiltrating lymphocytes
Categories
Ask authors/readers for more resources
The tumor microenvironment (TME) in breast cancer is composed of local factors, cancer cells, immune cells, and stromal cells from local and distant tissues. The interaction between cancer cells and their microenvironment is crucial for tumor growth, spread, and response to treatments. Research is increasingly focusing on manipulating non-cancerous components of the TME for breast cancer therapy.
Simple Summary The tumor microenvironment (TME) in breast cancer plays important roles in tumor behavior and treatment response, making its pathologic assessment critical for disease management. Analysis of the TME is not only limited to research-based technologies but is now incorporated into routine histopathologic reporting for practical clinical application. This review covers the current understanding of the TME of breast cancer, its pathologic assessment relevant for prognostication and treatment strategies, and the cancer therapies that interacts with and/or exploits the TME in breast cancer. As actionable targets are constantly being discovered in the TME, the future approach to breast cancer therapy is likely to combine cancer cell elimination and TME modulation. The tumor microenvironment (TME) in breast cancer comprises local factors, cancer cells, immune cells and stromal cells of the local and distant tissues. The interaction between cancer cells and their microenvironment plays important roles in tumor proliferation, propagation and response to therapies. There is increasing research in exploring and manipulating the non-cancerous components of the TME for breast cancer treatment. As the TME is now increasingly recognized as a treatment target, its pathologic assessment has become a critical component of breast cancer management. The latest WHO classification of tumors of the breast listed stromal response pattern/fibrotic focus as a prognostic factor and includes recommendations on the assessment of tumor infiltrating lymphocytes and PD-1/PD-L1 expression, with therapeutic implications. This review dissects the TME of breast cancer, describes pathologic assessment relevant for prognostication and treatment decision, and details therapeutic options that interacts with and/or exploits the TME in breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available